(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

552842

(43) International Publication Date
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number
WO 2004/089905 A1

(51) International Patent Classification[7]: C07D 213/76, 239/48, 487/08, 213/74, A61K 31/44, 31/505, A61P 13/12, 25/18

(21) International Application Number: PCT/EP2004/003872

(22) International Filing Date: 13 April 2004 (13.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/413,233 14 April 2003 (14.04.2003) US

(71) Applicant *(for all designated States except US)*: **ABBOTT GMBH & CO. KG** [DE/DE]; Max-Planck-Ring 2, 65205 Wiesbaden (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BRAJE, Wilfried** [DE/DE]; Unter dem Hopfenberge 15, 31737 Rinteln (DE). **HAUPT, Andreas** [DE/DE]; Schaelzigweg 52, 68723 Schwetzingen (DE). **LUBISCH, Wilfried** [DE/DE]; Haeusserstrasse 15, 69115 Heidelberg (DE). **GRANDEL, Roland** [DE/DE]; Birkenweg 49, 69221 Dossenheim (DE). **DRESCHER, Karla** [DE/DE]; Unteres Bieth 10, 69221 Dossenheim (DE). **GENESTE, Hervé** [FR/DE]; Rehbachstrasse 42, 67141 Neuhofen (DE). **UNGER, Liliane** [DE/DE]; Wollstr. 129, 67065 Ludwigshafen (DE). **SAUER, Daryl, R.** [US/US]; 23619 112th Street, Trevor, WI 53179 (US). **TURNER, Sean, C.** [GB/DE]; Lameystr. 21, 68165 Mannheim (DE).

(74) Agents: **KINZEBACH, Werner** et al.; Reitstötter, Kinzebach & Partner (GbR), Ludwigsplatz 4, 67059 Ludwigshafen (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR



(I)

(57) Abstract: The invention relates to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula (I) in which Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R^a which is/are selected, independently of each other, from halogen, CN, NO_2, $C0_2R^4$, COR^5, C_1-C_4-alkyl and C_1-C_4-haloalkyl; Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R^b, which is/are selected from halogen, NO_2, CN, $C0_2R^4$, COR^5, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_4-alkyl and C_1-C_4-haloalkyl, with it also being possible for two radicals R^b which are bonded to adjacent C atoms of Ar to be together C_3-C_4-alkylene; R^1 is hydrogen, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_4-alkyl, C_1-C_4-hydroxyalkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl, C_3-C_4-alkenyl or C_3-C_4-alkynyl; with the radicals n, R^1, R^2, R^3, R^4 and R^5 having the meanings given in the patent claims, to the N-oxides and to the physiologically tolerated acid addition salts of these compounds and to pharmaceutical compositions which comprise at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claims 1 to 10 and/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances for treating diseases which respond to influencing by dopamine D_3 receptor antagonists or agonists, in particular for treating diseases of the central nervous system and disturbances of kidney function.

WO 2004/089905 A1